3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Ovarian Neoplasms
16
Fallopian Tube Neoplasms
14
Sarcoma
5
Breast Neoplasms
5
Carcinoma, Ovarian Epithelial
4
Neoplasms
3
Neoplasm Metastasis
3
Triple Negative Breast Neoplasms
2
Sarcoma, Ewing
2
Multi-centric Castleman's Disease
2
Hodgkin Disease
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Vaccinia
1
Uterine Cervical Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Rhabdomyosarcoma
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
1
Recurrence
1
Peritoneal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Cancer Recurrent
1
Osteosarcoma
1
Macular dystrophy, corneal type 1
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphadenopathy
1
Interventions
pembrolizumab
22
Nivolumab
14
enfortumab vedotin
13
Gemcitabine
11
Specimen Handling
9
Magnetic Resonance Spectroscopy
9
Cisplatin
8
Carboplatin
8
sacituzumab govitecan
6
Docetaxel
6
avelumab
5
atezolizumab
5
Ipilimumab
5
durvalumab
4
Paclitaxel
4
cabozantinib
3
Taxes
3
Mitomycin
3
CTLA-4 Antigen
3
tislelizumab
2
relatlimab
2
erdafitinib
2
disitamab vedotin
2
Radiosurgery
2
Platinum
2
Oxaliplatin
2
Immunoglobulin G
2
Fluorouracil
2
Disulfides
2
ALT-803
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
liposomal doxorubicin
×
90 days
×
Clear all
No trials found.